Endo-2,3-Norbornanedicarboximide

• CAT Number: R062370
• CAS Number: 28871-95-6
• Molecular Formula: C9H11NO2
• Molecular Weight: 165.192
• Purity: ≥95%
• Storage: Store at -20°C
• IUPAC Name: (1R,2R,6S,7S)-4-azatricyclo[5.2.1.02,6]decane-3,5-dione
• InChI: InChI=1S/C9H11NO2/c11-8-6-4-1-2-5(3-4)7(6)9(12)10-8/h4-7H,1-3H2,(H,10,11,12)/t4-,5+,6-,7+
• InChIKey: RIVOBMOBWMOLDJ-UMRXKNAASA-N
• SMILES: C1CC2CC1C3C2C(=O)NC3=O

(3aR,4R,7S,7aS)-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione(CAS: 28871-95-6) is an intermediate in synthesizing Tripamide (T805560), which is a diuretic.

Reference

[1]. Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., Iwao, H.J.H.R. and Kario, K., 2009.
The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009).
Hypertens Res, 32(1), pp.3-107.

[2]. Ogihara, T., Saruta, T., Rakugi, H., Shimamoto, K., Ito, S., Matsuoka, H., Horiuchi, M., Imaizumi, T., Takishita, S., Higaki, J. and Katayama, S., 2009.
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
Abstract: The COLM study is an investigator-initiated trial comparing the combination therapy using an angiotensin II receptor blocker (ARB), olmesartan, and a calcium channel blocker (CCB) with that using an ARB and a diuretic in high-risk elderly hypertensive patients. Here we describe the rationale and study design. Olmesartan was administered concomitantly with a long-acting dihydropyridine CCB (ARB/CCB group) or with a low-dose diuretic (ARB/diuretic group) to elderly hypertensive patients with a history of or risk factors for cardiovascular disease. Cardiovascular morbidity and mortality as a primary end point were compared between the two groups, with the target blood pressure (BP) being <140 mm Hg for systolic BP and <90 mm Hg for diastolic BP. Safety and tolerability will also be investigated. A total of more than 4000 patients were recruited and will be followed up for at least 3 years.
Hypertension research, 32(2), pp.163-167.